Cervical Cancer
Researchers assessed ICD gene expressions to predict immunotherapy response and immune cell infiltration.
The global burden of cervical cancer, as well as cervical cancer mortality, is predicted to increase substantially by 2030.
Subgroup analyses of multiple diagnostic performance metrics in high vs low-income communities were also performed.
A study compared the screening performances of a tools used in cervical cancer screening in HIV-positive women.
Results were deduced from self-collected as well as clinician-obtained screening results.
Pembrolizumab plus chemoradiotherapy was shown to improve survival in advanced cervical cancer.
Pembrolizumab use is increasing among patients with recurrent cervical cancer.
Camrelizumab plus apatinib demonstrates robust and sustained efficacy in treating patients with advanced cervical cancer.
Advertisement
Expert Interviews on Oncology
Advertisement
DocWire News delivers the latest medical industry news, giving health care professionals the curated content most relevant to their fields and practices.
Get the latest medical updates and insights straight to your inbox.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.